OmniSeq Inc., a molecular diagnostic laboratory on the Buffalo Niagara Medical Campus, has a new CEO.
Margot P. Schoenborn, formerly the company's chief administrative officer, has been promoted to the position. She succeeds Mark Gardner, who remains on the board and is now senior vice president at Corza Health, a health care and life sciences company based in California.
Schoenborn joined OmniSeq in 2015, as Roswell Park Comprehensive Cancer Center was spinning the company off into a separate but affiliated commercial venture. It was formed out of research conducted at Roswell by OmniSeq founder and chairman Dr. Carl Morrisson, who remains on the faculty at the cancer center.
Roswell Park invested $25 million to develop a lung cancer test tailored to patients' unique genetic characteristics. OmniSeq's cancer tests let doctors customize cancer treatment to a patients' tumor and the molecular changes causing the cancer.
Schoenborn first joined the company as senior vice president, general counsel and corporate secretary. Before joining OmniSeq, Schoenborn was special assistant attorney general for New York, then deputy general counsel at Roswell Park.
OmniSeq employs about 50 scientists, technicians, technologists and other staff, according to the company.